Kosmos Energy Ltd. Common Shares (DE) vs Mesoblast Limited — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while Mesoblast Limited trades at $13.76 (market cap $1.83B). The key difference: Kosmos Energy Ltd. Common Shares (DE) and Mesoblast Limited are close in size by market cap, and Kosmos Energy Ltd. Common Shares (DE) is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and Mesoblast Limited for 15 Days on average.
| KOS | MESO | |
|---|---|---|
Market Cap | $1.66B | $1.83B |
Volume | 7,535,344 | 259,445 |
Sector | Energy | Health |
52-Week High | $3.27 | $20.96 |
52-Week Low | $0.87 | $13.19 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $4.30B | $1.91B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.895, down 2.63% with bearish technical signals. The company reported substantial revenue growth to $120M in 2026 but remains unprofitable with a net margin of -47.82%. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant milestones. The stock shows mixed sentiment with 45% analyst buy ratings against bearish technical indicators.
While MESO demonstrates strong revenue growth potential and pipeline progress, persistent losses and negative profitability metrics present substantial risk. The company's cash position of $161M provides runway, but investors face volatility from clinical trial outcomes and path to profitability challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →